Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
-
Publication number: 20140030332Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: January 6, 2012Publication date: January 30, 2014Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Mark S. Fineman
-
Publication number: 20140031419Abstract: The present disclosure relates to methods of inhibiting the ATPase activity of Na/K-ATPase without stimulating the receptor function, methods of blocking Na/K-ATPase interaction with Src, methods of inhibiting cell growth, and methods of abolishing ouabain-provoked signaling transduction in the heart of a subject, which includes providing an effective amount of at least one hydroxyl xanthone derivative.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: The University of ToledoInventors: Zi-Jian Xie, Joseph I. Shapiro, Shuyi Si, Zhongbing Zhang
-
Patent number: 8637087Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.Type: GrantFiled: November 23, 2009Date of Patent: January 28, 2014Assignee: JB Therapeutics Inc.Inventors: Bobby W. Sandage, Jr., Glenn L. Cooper
-
Publication number: 20140024687Abstract: The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases.Type: ApplicationFiled: September 20, 2013Publication date: January 23, 2014Inventors: Colleen Ann Conway, Brant Geoffrey Firestone, Leigh Zawel
-
Publication number: 20140018415Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.Type: ApplicationFiled: June 27, 2013Publication date: January 16, 2014Inventors: Christopher Lawrence Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
-
Publication number: 20140018416Abstract: A compound represented by formula (1), or a pharmaceutically acceptable salt thereof is effective as a therapeutic agent or a prophylactic agent for a corneal disease or sensory nerve damage due to corneal surgery, and as a regeneration accelerator for corneal sensory nerves: wherein R1 represents a hydrogen atom or a carboxyl group, R2 represents a hydrogen atom or a hydroxy group, R3 represents a hydrogen atom or a carboxyl group, and R4 represents a hydrogen atom or a hydroxy group.Type: ApplicationFiled: February 23, 2012Publication date: January 16, 2014Applicants: DAINIPPON SUMITOMO PHARMA CO., LTD, KEIO UNIVERSITYInventors: Hideyuki Okano, Kazuo Tsubota, Shigeto Shimmura, Masahiro Omoto, Akiyoshi Kishino, Miho Maeda
-
Publication number: 20130324596Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: ApplicationFiled: May 17, 2013Publication date: December 5, 2013Applicant: ECOBIOTICS LTDInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Publication number: 20130309330Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).Type: ApplicationFiled: January 24, 2012Publication date: November 21, 2013Applicant: Inceptum Research & Therapeutics, Inc.Inventor: Fabrizio G. Mastronardi
-
Publication number: 20130310448Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to Inhibit functions of ATR and FANCD2 on DNA replication, damage checkpoint, and repair; therefore, this composition can improve the cancer sensitivity and poor prognosis to DNA-damaging therapeutics.Type: ApplicationFiled: December 13, 2012Publication date: November 21, 2013Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Hui-Chun WANG, Yang-Chang WU, Fang-Rong CHANG, Chin-Chung WU
-
Patent number: 8580299Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: GrantFiled: June 9, 2009Date of Patent: November 12, 2013Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8580298Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: GrantFiled: June 9, 2009Date of Patent: November 12, 2013Assignee: Vivus, Inc.Inventors: Thomas Najaraian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8563754Abstract: A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other.Type: GrantFiled: January 28, 2011Date of Patent: October 22, 2013Assignee: New York UniversityInventors: Seth J. Orlow, Li Ni Komatsu
-
Publication number: 20130274323Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.Type: ApplicationFiled: June 5, 2013Publication date: October 17, 2013Inventors: Curtis J. Henrich, Heidi R. Bokesch, Laura K. Cartner, Richard W. Fuller, Kirk R. Gustafson, Kentaro Takada, James B. McMahon, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean
-
Patent number: 8546376Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.Type: GrantFiled: September 17, 2010Date of Patent: October 1, 2013Assignee: Almac Discovery LimitedInventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
-
Publication number: 20130251793Abstract: This invention relates to a pharmaceutical composition comprising a combination of phentermine in an immediate-release form and topiramate in an extended-release form. Further, it relates to processes for the preparation of the composition and a method of using the composition.Type: ApplicationFiled: March 21, 2013Publication date: September 26, 2013Applicant: RANBAXY LABORATORIES LIMITEDInventors: Anuj Kumar FANDA, Kumaravel VIVEK, Ravish SHARMA, Romi Barat SINGH, Ajay Kumar SINGLA
-
Publication number: 20130245070Abstract: The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof.Type: ApplicationFiled: March 9, 2012Publication date: September 19, 2013Applicant: THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: Rajiv R. Ratan, Marie T. Filbin
-
Patent number: 8530513Abstract: The invention relates to use of a diterpene from a coral, excavatolide B, or an analogue thereof for treating a disease associated with inducible nitric oxide synthase, cyclooxygenase-2 and/or matrix metalloproteinase. The invention also relates to use of a diterpene from a coral, excavatolide B, and an analogue thereof for treating a disease associated with TNF-? and/or IL-6 over-expression.Type: GrantFiled: December 21, 2012Date of Patent: September 10, 2013Assignee: National Sun Yat-Sen UniversityInventors: Jyh-Horng Sheu, Ning-Sun Yang, Wen-Chi Wei, Chiung-Yao Huang
-
Publication number: 20130217761Abstract: The present invention relates to the effects of the epimeric mixture of cinchonains Ia and Ib on pathologies that involve alterations in the cardiovascular system, in combating, preventing and reverting ventricular fibrillation in human beings and animals, especially for combating spontaneous or electric-stimulus-induced ventricular fibrillation, to revert spontaneous or electric-stimulus-induced ventricular fibrillations, for preventing ventricular fibrillation, for the treatment of ventricular fibrillation of any etiology or for the treatment of post-fibrillation to maintain normal cardiac rhythm. The present invention further relates to methods for the synthesis of an epimeric mixture of the chemical substances cinchonain Ia and Ib. The present invention also relates to the use of these chemical substances in reverting/combating ventricular fibrillation and/or in protecting against ventricular fibrillation.Type: ApplicationFiled: April 5, 2013Publication date: August 22, 2013Applicant: Laboratorio Catarinense S/AInventor: Laboratorio Catarinense S/A
-
Publication number: 20130211371Abstract: A liquid or ointment formulation for the treatment of a skin condition associated with leukocyte accumulation in the skin includes a therapeutic compound selected to reduce leukocyte accumulation in the skin and an aqueous solution of an organic solvent. The organic solvent increases skin permeability. A method of treating a skin condition associated with leukocyte accumulation in the skin includes the steps of applying topically a liquid formulation of a photosensitizer to a skin lesion of a patient afflicted with the skin condition and exposing the skin lesion to a light source.Type: ApplicationFiled: April 20, 2011Publication date: August 15, 2013Applicant: Hy Biopharma, Inc.Inventors: Alfonso J. Tobia, Bernard E. Cabana, Alain H. Rook
-
Publication number: 20130210771Abstract: This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.Type: ApplicationFiled: February 13, 2013Publication date: August 15, 2013Applicant: IRM LLCInventor: Novartis AG
-
Publication number: 20130210906Abstract: The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.Type: ApplicationFiled: February 15, 2013Publication date: August 15, 2013Applicant: HONG KONG BAPTIST UNIVERSITYInventor: HONG KONG BAPTIST UNIVERSITY
-
Publication number: 20130209534Abstract: A substrate of polymeric material for wound care contains at least one oleous antimicrobial and/or helping tissue regeneration substance that is selected from Hyperforin, Adhyperforin, 1-3 Diapigenin, 11-8 Diapigenin, Rutin, Quercetin, Hypericin, Azadirachtin ?-?, Nimbin, Nimbidin, Salanin, Gallic Acid, Gedunin and combinations thereof.Type: ApplicationFiled: June 4, 2012Publication date: August 15, 2013Applicant: MOSES S.R.L.Inventors: Chiara GUALANDI, Maria Letizia FOCARETE, Andrea ZUCCHELLI, Maria Letizia IABICHELLA
-
Publication number: 20130202722Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.Type: ApplicationFiled: February 7, 2012Publication date: August 8, 2013Inventor: Omar M. Amin
-
Publication number: 20130202570Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.Type: ApplicationFiled: September 20, 2012Publication date: August 8, 2013Inventor: Omar M. Amin
-
Publication number: 20130189380Abstract: The invention discloses herbal ingredients derived from Sphaeranthus indicus standardized to at least one frullanolide/eudesmanoid sesquiterpene compound and their compositions as natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a mammal. The invention further includes the use of ingredients and compositions for food ingredient formulations such as dietary supplement, food ingredient, beverage, snack or energy drink containing the above said herbal ingredient(s) for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal.Type: ApplicationFiled: March 11, 2013Publication date: July 25, 2013Applicant: LAILA NUTRACEUTICALSInventor: Laila Nutraceuticals
-
Publication number: 20130183289Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 18, 2013Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Publication number: 20130184475Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: ApplicationFiled: July 8, 2011Publication date: July 18, 2013Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANNA, UNITED STATES DEPARTMENT OF AGRICULTUREInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Publication number: 20130184214Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: ApplicationFiled: February 10, 2012Publication date: July 18, 2013Inventor: Steven Hoffman
-
Publication number: 20130183388Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.Type: ApplicationFiled: February 26, 2013Publication date: July 18, 2013Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCHInventor: Lankenau Institute for Medical Research
-
Patent number: 8486993Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.Type: GrantFiled: July 7, 2011Date of Patent: July 16, 2013Assignee: Veloxis Pharmaceuticals A/SInventor: Per Holm
-
Publication number: 20130171060Abstract: A system for energy upconversion and/or down conversion and a system for producing a photostimulated reaction in a medium. These systems include 1) a nanoparticle configured, upon exposure to a first wavelength ?1 of radiation, to generate a second wavelength ?2 of radiation having a higher energy than the first wavelength ?1 and 2) a metallic structure disposed in relation to the nanoparticle. A physical characteristic of the metallic structure is set to a value where a surface plasmon resonance in the metallic structure resonates at a frequency which provides a spectral overlap with either the first wavelength ?1 or the second wavelength ?2, or with both ?1 and ?2. The system for producing a photostimulated reaction in a medium includes a receptor disposed in the medium in proximity to the nanoparticle which, upon activation by the second wavelength ?2, generates the photostimulated reaction.Type: ApplicationFiled: January 2, 2013Publication date: July 4, 2013Applicant: IMMUNOLIGHT, LLCInventor: IMMUNOLIGHT, LLC
-
Publication number: 20130156753Abstract: The present invention provides novel uses of the cAMP/PKA/HDAC5 pathway for the treatment and prevention of myopathies.Type: ApplicationFiled: July 31, 2011Publication date: June 20, 2013Applicant: UNIVERSITY OF ROCHESTERInventor: Zheng-gen Jin
-
Publication number: 20130142848Abstract: The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone.Type: ApplicationFiled: August 4, 2011Publication date: June 6, 2013Inventors: Miho Maeda, Akiyoshi Kishino, Akihiko Sano, Hideyuki Okano, Masaya Nakamura, Liang Zhang
-
Patent number: 8455539Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.Type: GrantFiled: October 15, 2012Date of Patent: June 4, 2013Assignee: Wyeth LLCInventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
-
Publication number: 20130131088Abstract: The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity.Type: ApplicationFiled: January 13, 2011Publication date: May 23, 2013Applicant: UNIVERSITY HEALTH NETWORKInventors: Linda Penn, Aaron Schimmer, Aleksandra Pandyra
-
Publication number: 20130116247Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.Type: ApplicationFiled: April 5, 2011Publication date: May 9, 2013Applicant: MANNKIND CORPORATIONInventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
-
Publication number: 20130102659Abstract: The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering a salvinorin compound to produce vasodilatory effect and organ protective effect from hypoxia/ischemia and reperfusion. The invention further relates to treating various diseases or disorders.Type: ApplicationFiled: June 29, 2011Publication date: April 25, 2013Inventor: Renyu Liu
-
Publication number: 20130072477Abstract: The present invention relates to a therapeutic or prophylactic method for treating Parkinson's disease by administering an effective amount of a compound having a phosphodiesterase 10 inhibitory activity; and also relates to a pharmaceutical composition for treatment or prophylaxis of Parkinson's disease comprising as an active ingredient a compound having a phosphodiesterase 10 inhibitory activity. Moreover, the present invention relates to a method for enhancing dopamine signal in the brain, which comprises administering an effective amount of a compound having a phosphodiesterase 10 inhibitory activity; and also relates to pharmaceutical composition for enhancing dopamine signal in brain comprising as an active ingredient a compound having a phosphodiesterase 10 inhibitory activity.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: MITSUBISHI TANABE PHARMA COPORATIONInventor: MITSUBISHI TANABE PHARMA COPORATION
-
Patent number: 8389568Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.Type: GrantFiled: March 14, 2008Date of Patent: March 5, 2013Assignee: Lankenau Institute for Medical ResearchInventors: George C. Prendergast, William P. Malachowski, Alexander J. Muller
-
Patent number: 8389569Abstract: Novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and a method for preparing the same.Type: GrantFiled: October 2, 2008Date of Patent: March 5, 2013Assignee: Universite Joseph FourierInventors: Yung-Sing Wong, Marine Aimée Peuchmaur, Eric Marechal, Cyrille Botte, Henri Joseph Vial, Nadia Saidani
-
Patent number: 8383672Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: GrantFiled: June 9, 2011Date of Patent: February 26, 2013Assignee: Kiadis Pharma Canada Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20130012576Abstract: The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a Monascus fermented product with acetone for three times; elevating the concentration of the Monascus fermented product by a process of decompress concentration; and extracting the monascin and the ankaflavin from the Monascus fermented product with a silica gel column chromatography, a Sephadex LH-20 column chromatography, the silica gel column chromatography, and a preparative high performance liquid chromatography sequentially.Type: ApplicationFiled: August 23, 2011Publication date: January 10, 2013Applicant: SUNWAY BIOTECH CO., LTD.Inventors: Tzu-Ming PAN, Chun-Lin LEE, Chen-Lun WU
-
Publication number: 20120322754Abstract: The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose.Type: ApplicationFiled: August 17, 2010Publication date: December 20, 2012Applicant: YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INCInventors: Tae Sun Park, Ha Won Kim, Wan Kyun Hwang
-
Publication number: 20120321714Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.Type: ApplicationFiled: March 26, 2012Publication date: December 20, 2012Applicant: Ipsen Pharma S.A.S.Inventors: Nathalie MONDOLY, Bertrand Poirot, Anne Brochard, Joël Richard, Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Julie Linol, Marie-Noêlle Petit, Barry Victor Llyod Potter, Lok, Wai Lawrence Woo
-
Publication number: 20120302630Abstract: Na/K-ATPase/Src ligands, assays and uses thereof are disclosed.Type: ApplicationFiled: September 9, 2010Publication date: November 29, 2012Applicants: CHINESE ACADEMY OF MEDICAL SCIENCES, UNIVERSITY OF TOLEDOInventors: Zi-Jian Xie, Joseph I. Shapiro, Shuyi Si, Zhongbing Zhang
-
Publication number: 20120282255Abstract: The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated.Type: ApplicationFiled: April 6, 2012Publication date: November 8, 2012Inventor: Greg Plucinski
-
Publication number: 20120277297Abstract: The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marrnesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7 -methoxycoumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions possess a high degree of acetylcholinesterase inhibitory (AChE) property.Type: ApplicationFiled: April 30, 2012Publication date: November 1, 2012Applicant: Council of Scientific and Industrial ResearchInventors: Janaswamy Madhusudana Rao, Bhimapaka China Raju, Pullela Venkata Srinivas, Katragadda Suresh Babu, Jhillu Singh Yadav, Kondapuram Vijaya Raghvan, Hemant Kumar Singh, Chandiswar Nath
-
Patent number: 8298576Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.Type: GrantFiled: November 16, 2007Date of Patent: October 30, 2012Assignee: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
-
Publication number: 20120264819Abstract: The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject.Type: ApplicationFiled: April 20, 2012Publication date: October 18, 2012Inventors: Navindra P. Seeram, David Heber
-
BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS
Publication number: 20120264736Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.Type: ApplicationFiled: October 6, 2011Publication date: October 18, 2012Applicant: Schering CorporationInventors: Theodros Asberom, Thomas A. Bara, Chad E. Bennett, Duane A. Burnett, Mary Ann Caplen, John W. Clader, David J. Cole, Martin S. Domalski, Hubert B. Josien, Chad E. Knutson, Hongmei Li, Mark D. McBriar, Dmitri A. Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamgara K. Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Ruo Xu, Zhiqiang Zhao